Rani Therapeutics Holdings (RANI) Cash & Equivalents (2020 - 2026)

Rani Therapeutics Holdings' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $9.6 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 4.62% year-over-year to $9.6 million in Q1 2026; TTM through Mar 2026 was $9.6 million, a 4.62% decrease from a year earlier, with the FY2025 full-year figure at $18.6 million, up 394.9% from the prior year.
• Cash & Equivalents fell to $9.6 million in Q1 2026 per RANI's latest filing, from $18.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $27.2 million in Q3 2022 and bottomed at $3.8 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $7.6 million (2023), against an average of $10.9 million.
• Across the five-year window, Cash & Equivalents plunged 81.73% in 2023 and surged 394.9% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $27.0 million in 2022, then sank by 78.29% to $5.9 million in 2023, then plunged by 35.85% to $3.8 million in 2024, then surged by 394.9% to $18.6 million in 2025, then sank by 48.2% to $9.6 million in 2026.
• Per Business Quant, the three latest RANI Cash & Equivalents figures stand at $9.6 million (Q1 2026), $18.6 million (Q4 2025), and $4.1 million (Q3 2025).